Short answer: no. There is no published study that puts CBN, CBD and CBG head-to-head in the same trial and measures which works better for a given condition. What exists instead is three separate, very unevenly sized bodies of research — and a product label that often lists all three together as if the evidence behind them were equally sized too. This guide walks through what is actually known about each compound on its own, why a blend does not automatically inherit the evidence for its individual ingredients, and what to ask a pharmacist or physician before you buy.
Are there direct comparisons between CBN, CBD and CBG?
Not in the clinical sense. CBD, CBG and CBN are all non-intoxicating compounds found in the cannabis plant, and because they are chemically related and often extracted together, marketing copy treats them as interchangeable variations on a theme. The research does not support that framing.
The National Institute on Drug Abuse names CBN directly as one of several cannabinoids with limited research on its health effects, grouping it with other lesser-studied compounds such as delta-8-THC and THCV. CBG has more human data than CBN but far less than CBD — most of its findings come from lab and animal research, with one notable exception described below. CBD is the clear outlier: it has the deepest literature of the three, including the trials behind the single FDA-approved CBD drug product, which treats seizures associated with specific rare epilepsy syndromes rather than general wellness complaints.
Because no study has tested all three compounds against each other under the same conditions, any claim that one “beats” another for a specific use is not something the current research can support.
What each compound actually is
- CBD (cannabidiol): The most studied of the three. Non-intoxicating. The only cannabinoid with an FDA-approved prescription drug product, used for specific seizure disorders under medical supervision — not a general approval for wellness use.
- CBG (cannabigerol): Sometimes called a precursor cannabinoid because other cannabinoids, including CBD and THC, form from it earlier in the plant’s growth cycle. Most of the published evidence is preclinical, but a 2024 human trial (below) is a genuine exception.
- CBN (cannabinol): Forms as THC ages and breaks down, which is why it is associated with older cannabis material. Frequently marketed for sleep. Human research on CBN specifically is sparse enough that NIDA groups it with other understudied cannabinoids rather than treating it as a settled compound.
The one real human trial worth knowing about
Researchers at Washington State University, working with colleagues at UCLA, ran what they describe as the first human clinical trial of isolated CBG. It was double-blind and placebo-controlled, involved 34 healthy adult cannabis users, and found that a single oral dose of CBG reduced self-reported anxiety and stress compared to placebo. It did not find a significant improvement in mood. The researchers describe the results as an early step and say more studies are needed to understand CBG’s benefits and safety — this was one acute-dose trial in a specific, small group, not a confirmed treatment.
Does a blend inherit the evidence for each ingredient?
No — and this is the gap most product pages skip over. A gummy or tincture that lists CBD, CBG and CBN on the same label is not three separately-proven ingredients stacked together. It is a new formulation, at whatever ratio and dose the manufacturer chose, that has not itself been studied. The evidence behind CBD’s seizure indication, for example, comes from a specific purified formulation at a specific dose studied in a specific patient population — it does not transfer to a gummy that also contains CBG and CBN at ratios the label may not even specify.
This matters practically, too. The FDA has reported finding CBD products that did not contain the amount of CBD stated on the label, and NIDA notes that some products marketed as CBD have been found to contain THC. If a single ingredient’s stated amount can be unreliable, a three-cannabinoid blend’s claimed ratio deserves at least the same scrutiny before you treat it as a known quantity.
Pilot and acute studies do not validate a retail product
Even where a study exists, it is worth asking what kind of study it is before applying it to a bottle on a shelf. Three distinctions matter:
- Preclinical versus human: Much of the published CBG and CBN research comes from cell cultures or animal models. Findings at that stage frequently do not replicate in humans, and none of these studies tested a commercial retail product.
- Pilot versus confirmatory: The CBG anxiety trial above is a first-of-its-kind pilot study in 34 people. That is a reason for more research, not a basis for a “clinically proven” claim on a product label.
- Acute versus long-term: A study measuring what happens after one dose says nothing about what happens after months of regular use. The FDA has specifically said it does not yet know the effects of sustained daily CBD use, and that open question applies with even less data to CBG and CBN.
None of this means these compounds do nothing. It means the step between “a pilot study measured an effect” and “this retail product treats your condition” is a step the current evidence does not make.
A worksheet for reading any CBN, CBD or CBG label
Before you buy or take a product that lists any of these three compounds, it helps to write down five things rather than rely on the sales page’s framing:
- Product form: Gummy, tincture, capsule, topical — absorption and dosing accuracy differ by form, and a study on one form does not automatically apply to another.
- Cannabinoid named on the label: Which of CBD, CBG or CBN is actually listed, at what amount per serving, and whether a lab report — not just a marketing page — backs that number up.
- Legal or safety question: Hemp-derived CBD products occupy a legal gray area. It is currently illegal under federal law to market CBD by adding it to food or labeling it as a dietary supplement, regardless of state rules on sale. Note the specific state and federal status where you are buying.
- Relevant source and date: Which study or agency statement you’re relying on, and when it was published. Cannabinoid research moves quickly enough that a claim from a few years ago may already be outdated.
- What remains unknown: Write down the specific question the available research has not answered for this product — dosing, interaction with your other medications, long-term use, or anything else. This is the line to bring to a pharmacist or doctor.
Safety questions worth asking before you start
The FDA’s review of CBD — the best-studied of the three compounds — found risks that are worth considering for CBG and CBN products too, given the overlapping extraction and sales channels: potential liver injury, interactions with other medications, changes in alertness, and reproductive effects reported in animal studies. If you take any prescription or over-the-counter medication, have a liver, kidney, heart or thyroid condition, or are pregnant or breastfeeding, that is a conversation for your doctor or pharmacist before adding any of these three compounds — alone or blended — to your routine.
Your next step
If a specific product’s marketing is what brought you here — for instance, a full-spectrum CBD gummy marketed with a mix of cannabinoids — read the study limitations behind any claim before you bring it up with a clinician. Our coverage of Golden Touch Fusion CBD Gummies walks through how one such product’s own terms and sales page describe its ingredients, billing and refund process, if that is the product that led you here.
This article is for general information purposes only and does not constitute medical advice. Consult your doctor, pharmacist or qualified healthcare provider before starting, stopping or combining any cannabinoid product.